drugset / Trial / NCT05299164
GVM±R in Patients With Relapsed or Refractory Aggressive NHL
Phase 1
Active not recruiting
18 enrolled
Institute of Hematology & Blood Diseases Hospital, China
CSPC Ouyi Pharmaceutical Co., Ltd. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a prospective, dose-escalation clinical study to evaluate the safety and efficacy of GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).
Timeline
- Start
- 2022-05-15
- Primary completion
- 2023-12-18
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitoxantrone | Small molecule | 16 mg/m2 | — |
| Subject | Mitoxantrone | Small molecule | 18 mg/m2 | — |
| Subject | Mitoxantrone | Small molecule | 20 mg/m2 | — |
| Subject | Mitoxantrone | Small molecule | 22 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 800 mg/m2 | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | Vinorelbine | Small molecule | 25 mg/m2 | — |